Crossmark

Incidence of thrombotic complications related to weight-based dosing of activated prothrombin complex concentrate (aPCC) for reversal of apixaban and rivaroxaban in obese patients

Crossref DOI link: https://doi.org/10.1007/s11239-021-02605-1

Published Online: 2021-11-17

Published Print: 2022-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Whitaker, Caitlyn

McKinney, Amanda

Bollig, Reagan

Hieb, Nathan

Roberts, R. Frank Jr.

Rowe, A. Shaun
License Information

Text and Data Mining valid from 2021-11-17

Version of Record valid from 2021-11-17
More Information

Article History

Accepted: 4 November 2021

First Online: 17 November 2021

Declarations

:

: The authors have no relevant financial or non-financial interests to disclose.

: Ethical approval was waived by the local Ethics Committee of University of Tennessee Medical Center in view of the retrospective nature of the study and all the procedures being performed were part of the routine care.

: Not applicable.

Document is current

Any future updates will be listed below